Impact of recurrence pattern in patients undergoing a second surgery for recurrent glioblastoma.
Glioblastoma
Pattern of failure
Recurrent glioblastoma
Second surgery
Journal
Acta neurologica Belgica
ISSN: 2240-2993
Titre abrégé: Acta Neurol Belg
Pays: Italy
ID NLM: 0247035
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
28
03
2021
accepted:
26
07
2021
pubmed:
17
8
2021
medline:
9
4
2022
entrez:
16
8
2021
Statut:
ppublish
Résumé
The impact of different patterns of glioblastoma (GBM) recurrence has not yet been fully established in patients suitable for a second surgery. Through the present observational study carried out at Pisa University Hospital, we aimed to investigate how different patterns of GBM failure influence second surgery outcomes. Overall survival (OS) and post-recurrence survival (PRS) were assessed according to clinical characteristics, including pattern of recurrence, in a prospective cohort of recurrent GBM patients. Survival curves were calculated using the Kaplan-Meier method and the log-rank test was applied to evaluate the differences between curves. Patients with local recurrence had better OS than patients with non-local one, 24.1 versus 18.2 months, respectively [P = 0.015, HR = 1.856 (1.130-3.050)]. The second surgery conferred an advantage in OS respect to non-operated patients, however, this advantage was more evident in patients with local recurrence [P = 0.002 with HR 0.212 (95% CI 0.081-0.552) and P = 0.029 with HR = 0.522 (95% CI 0.291-0.936), respectively]. The recurrence pattern can influence the outcome of patients with recurrent GBM suitable for a second surgery.
Identifiants
pubmed: 34396487
doi: 10.1007/s13760-021-01765-4
pii: 10.1007/s13760-021-01765-4
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
441-446Informations de copyright
© 2021. Belgian Neurological Society.
Références
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330
doi: 10.1056/NEJMoa043330
pubmed: 15758009
pmcid: 15758009
Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP et al (2020) Glioblastoma in adults: a society for neuro-oncology (SNO) and European society of neuro-oncology (EANO) consensus review on current management and future directions. Neuro Oncol 22:1073–1113. https://doi.org/10.1093/neuonc/noaa106
doi: 10.1093/neuonc/noaa106
pubmed: 32328653
pmcid: 7594557
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C et al (2019) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012–2016. Neuro Oncol 21:v1–v100. https://doi.org/10.1093/neuonc/noz150
doi: 10.1093/neuonc/noz150
pubmed: 31675094
pmcid: 31675094
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G et al (2020) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol. https://doi.org/10.1038/s41571-020-00447-z
doi: 10.1038/s41571-020-00447-z
pubmed: 33293629
pmcid: 7904519
Pasqualetti F, Gonnelli A, Molinari A, Cantarella M, Montrone S, Cristaudo A et al (2018) Different timing to use bevacizumab in patients with recurrent glioblastoma: early. Anticancer Res 38:5877–5881. https://doi.org/10.21873/anticanres.12930
doi: 10.21873/anticanres.12930
pubmed: 30275213
Birk HS, Han SJ, Butowski NA (2017) Treatment options for recurrent high-grade gliomas. CNS Oncol 6:61–70. https://doi.org/10.2217/cns-2016-0013
doi: 10.2217/cns-2016-0013
pubmed: 28001091
Navarria P, Minniti G, Clerici E, Tomatis S, Pinzi V, Ciammella P et al (2019) Re-irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic factors assessment. A multicenter study of the radiation oncology Italian association (AIRO). J Neurooncol 142:59–67. https://doi.org/10.1007/s11060-018-03059-x
doi: 10.1007/s11060-018-03059-x
pubmed: 30515706
Kruser TJ, Bosch WR, Badiyan SN, Bovi JA, Ghia AJ, Kim MM et al (2019) NRG brain tumor specialists consensus guidelines for glioblastoma contouring. J Neurooncol 143:157–166. https://doi.org/10.1007/s11060-019-03152-9
doi: 10.1007/s11060-019-03152-9
pubmed: 30888558
pmcid: 6483830
Fabrini MG, Perrone F, De Liguoro M, Coppola M, Santi S, Solito B et al (2010) A single-institutional brachytherapy experience in the management of esophageal cancer. Brachytherapy 9:185–191. https://doi.org/10.1016/j.brachy.2009.08.006
doi: 10.1016/j.brachy.2009.08.006
pubmed: 19875341
Bette S, Barz M, Huber T, Straube C, Schmidt-Graf F, Combs SE et al (2018) Retrospective analysis of radiological recurrence patterns in glioblastoma, their prognostic value and association to postoperative infarct volume. Sci Rep 8:4561. https://doi.org/10.1038/s41598-018-22697-9
doi: 10.1038/s41598-018-22697-9
pubmed: 29540809
pmcid: 5852150
Patil CG, Yi A, Elramsisy A, Hu J, Mukherjee D, Irvin DK et al (2012) Prognosis of patients with multifocal glioblastoma: a case-control study. J Neurosurg 117:705–711. https://doi.org/10.3171/2012.7.JNS12147
doi: 10.3171/2012.7.JNS12147
pubmed: 22920963
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972. https://doi.org/10.1200/JCO.2009.26.3541
doi: 10.1200/JCO.2009.26.3541
pubmed: 20231676
Brandes AA, Bartolotti M, Tosoni A, Poggi R, Bartolini S, Paccapelo A et al (2016) Patient outcomes following second surgery for recurrent glioblastoma. Future Oncol 12:1039–1044. https://doi.org/10.2217/fon.16.9
doi: 10.2217/fon.16.9
pubmed: 26880307
Montemurro N, Perrini P, Blanco MO, Vannozzi R (2016) Second surgery for recurrent glioblastoma: a concise overview of the current literature. Clin Neurol Neurosurg 142:60–64. https://doi.org/10.1016/j.clineuro.2016.01.010
doi: 10.1016/j.clineuro.2016.01.010
pubmed: 26811867
Montemurro N, Fanelli GN, Scatena C, Ortenzi V, Pasqualetti F, Mazzanti CM et al (2021) Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: a single-center retrospective series. Clin Neurol Neurosurg 207:106735. https://doi.org/10.1016/j.clineuro.2021.106735
doi: 10.1016/j.clineuro.2021.106735
pubmed: 34119900
Perrini P, Gambacciani C, Weiss A, Pasqualetti F, Delishaj D, Paiar F et al (2017) Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis. J Neurooncol 131:585–591. https://doi.org/10.1007/s11060-016-2330-7
doi: 10.1007/s11060-016-2330-7
pubmed: 27844310
Ortega A, Sarmiento JM, Ly D, Nuño M, Mukherjee D, Black KL et al (2016) Multiple resections and survival of recurrent glioblastoma patients in the temozolomide era. J Clin Neurosci 24:105–111. https://doi.org/10.1016/j.jocn.2015.05.047
doi: 10.1016/j.jocn.2015.05.047
pubmed: 26671314
Goldman DA, Hovinga K, Reiner AS, Esquenazi Y, Tabar V, Panageas KS (2018) The relationship between repeat resection and overall survival in patients with glioblastoma: a time-dependent analysis. J Neurosurg 129:1231–1239. https://doi.org/10.3171/2017.6.JNS17393
doi: 10.3171/2017.6.JNS17393
pubmed: 29303449
pmcid: 6392195
Soffietti R, Trevisan E, Bertero L, Cassoni P, Morra I, Fabrini MG et al (2014) Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian association of neuro-oncology). J Neurooncol 116:533–541. https://doi.org/10.1007/s11060-013-1317-x
doi: 10.1007/s11060-013-1317-x
pubmed: 24293233
Zhao YH, Wang ZF, Pan ZY, Péus D, Delgado-Fernandez J, Pallud J et al (2019) A meta-analysis of survival outcomes following reoperation in recurrent glioblastoma: time to consider the timing of reoperation. Front Neurol 10:286. https://doi.org/10.3389/fneur.2019.00286
doi: 10.3389/fneur.2019.00286
pubmed: 30984099
pmcid: 6448034
Tully PA, Gogos AJ, Love C, Liew D, Drummond KJ, Morokoff AP (2016) Reoperation for recurrent glioblastoma and its association with survival benefit. Neurosurgery 79:678–689. https://doi.org/10.1227/NEU.0000000000001338
doi: 10.1227/NEU.0000000000001338
pubmed: 27409404
Chaichana KL, Zadnik P, Weingart JD, Olivi A, Gallia GL, Blakeley J et al (2013) Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg 118:812–820. https://doi.org/10.3171/2012.9.JNS1277
doi: 10.3171/2012.9.JNS1277
pubmed: 23082884
Azoulay M, Santos F, Shenouda G, Petrecca K, Oweida A, Guiot MC et al (2017) Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution. J Neurooncol 132:419–426. https://doi.org/10.1007/s11060-017-2383-2
doi: 10.1007/s11060-017-2383-2
pubmed: 28374095
Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280. https://doi.org/10.1200/JCO.1990.8.7.1277
doi: 10.1200/JCO.1990.8.7.1277
pubmed: 2358840